Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo
Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
12/2003
12/04/2003WO2003099210A2 Methods of modulating tubulin deacetylase activity
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003050499A3 Use of a labeled ligand having human cd4 specificity
12/04/2003WO2003048328A3 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
12/04/2003WO2002070555A3 Method of modulating the proliferation of medullary thyroid carcinoma cells
12/04/2003US20030225309 Radioactive compositions and methods of use thereof
12/04/2003US20030225150 Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
12/04/2003US20030224443 Novel epithelial tissue imaging agent
12/04/2003US20030223994 Protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the
12/04/2003CA2486173A1 Cell delivery fluid for prevention of cell settling in delivery system
12/04/2003CA2485988A1 Methods of modulating tubulin deacetylase activity
12/04/2003CA2478833A1 Anti-.alpha.v.beta.6 antibodies
12/03/2003EP1366778A2 Systems for the intrapulmonary delivery of aerosolized aqueous formulations
12/03/2003EP1365813A2 Ascorbic acid analogs for metalloradiopharmaceuticals
12/03/2003EP1123301B1 Chelating agents for radioimmunotherapy
12/03/2003EP0701457B1 Systems for the intrapulmonary delivery of aerosolized aqueous formulations
12/02/2003US6656448 Matrix metalloproteinase inhibitors
11/2003
11/27/2003WO2003097105A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent (s)
11/27/2003WO2003097052A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/27/2003WO2003097015A1 Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane
11/27/2003WO2003096978A2 Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (pet) imaging for the brain serotonin transporters
11/27/2003WO2003076469A3 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
11/27/2003WO2003059942A9 Peptides and peptidomimetics having anti-proliferative activity and their use
11/27/2003WO2003057837A3 Methods for using anti-muc18 antibodies
11/27/2003WO2002092771A3 Specific binding proteins and uses thereof
11/27/2003US20030220470 Methods for the purification of stable radioiodine conjugates
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220331 6-Azauracil derivatives as IL-5 inhibitors
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220233 Radiolabeled annexins
11/27/2003US20030219789 36P6D5: secreted tumor antigen
11/27/2003US20030219441 Combined methods and compositions for coagulation and tumor treatment
11/27/2003US20030219378 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003US20030219377 Brain disorders; Alzheimer's disease
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2486307A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s)
11/26/2003EP1364964A1 Radiolabeled annexingalactose conjugates
11/26/2003EP1363954A2 Polymer precursors of radiolabeled compounds, and methods of making and using the same
11/26/2003EP1363920A1 Modified psma ligands and uses related thereto
11/26/2003EP1363667A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
11/26/2003EP1363538A2 Enhanced ultrasound detection with temperature dependent contrast agents
11/26/2003EP0871492B1 Mesothelium antigen and methods and kits for targeting it
11/25/2003US6653299 Labelled factor XIIIa substrates
11/25/2003US6653104 Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
11/20/2003WO2003095457A1 Adenosine a3 receptor modulators
11/20/2003WO2003094976A1 Lyophilized edible food incorporating a marker
11/20/2003WO2002058531A8 Ingestible device
11/20/2003US20030216778 Composite staple for completing an anastomosis
11/20/2003US20030216609 Delivery methods, systems and components for use with radiopharmaceutical substances
11/20/2003US20030216352 Multicomponent complex for use with a substrate
11/20/2003US20030216337 Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system
11/20/2003US20030216317 Protein having cell-recognizing activity and/or cytocidal activity
11/20/2003US20030215490 Therapeutic liposome composition and method of preparation
11/20/2003US20030215386 Radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog.
11/20/2003CA2483696A1 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
11/20/2003CA2451081A1 Adenosine a<sb>3</sb> receptor modulators
11/19/2003EP1362868A2 Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
11/19/2003EP1362861A1 Macrocyclic chelants for metallopharmaceuticals
11/19/2003EP1362061A2 Antibodies that bind both bcma and taci
11/19/2003EP1362039A1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
11/19/2003EP1361899A2 Devices and methods for the treatment of cancer
11/19/2003EP1361898A2 Modulated release particles for aerosol delivery
11/19/2003EP1361875A2 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
11/19/2003EP0767673B1 Methods for reduced renal uptake of antibody fragments
11/19/2003EP0733066B1 Pretargeting methods and compounds
11/18/2003US6649614 Psychological disorders
11/18/2003US6649142 Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system
11/13/2003WO2003093478A1 Immunoconjugates for the treatment of tumours
11/13/2003WO2003093412A2 Tumor imaging compounds
11/13/2003WO2003092744A2 Benzothienyl analogue of somatostatin, selective for certain somatostatin receptors
11/13/2003WO2003092743A1 Radiopharmaceutical formulations
11/13/2003WO2003092742A1 Vitamin-targeted imaging agents
11/13/2003WO2003033654A3 Direct targeting binding proteins
11/13/2003WO2002057290A8 Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
11/13/2003US20030212007 Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent
11/13/2003US20030211132 Method for reducing radioactivity in the human body
11/13/2003US20030211042 Measuring stomach discharging; analyzing emisison in breath; calibration
11/13/2003US20030211038 Calibration sensitive toxicity to radioimmunotherapy; administering radioactive antibodies; measurement bone marrow
11/13/2003US20030211037 Determining effects of external stimuli on the brain using PET
11/13/2003US20030211035 Emulsion/aggregation polymeric microspheres for biomedical applications and methods of making same
11/13/2003CA2484345A1 Folate-targeted imaging agents
11/13/2003CA2462879A1 Immunoconjugates for the treatment of tumours
11/12/2003EP1360208A1 Induvidualized anti-cancer antibodies
11/12/2003EP1359943A2 Biotin-derivates and their conjugates with chelating agents
11/12/2003EP1359845A2 Ingestible device
11/12/2003EP1246830B1 Macrocyclic chelants for metallopharmaceuticals
11/12/2003CN1455683A Drugs for diagnosis of tissue-reproductive activity or treatment of proliferative disease
11/11/2003US6645484 Endothelial cell transmembrane tyrosine kinase ligand
11/11/2003US6645463 Blood-pool selective carrier for lipophilic imaging agents
11/06/2003WO2003090789A1 Method for obtaining a 2-18f-fluor-2-deoxy-d-glucose (18f-fdg) - solution
11/06/2003WO2003090710A1 Lapachone delivery systems, compositions and uses related thereto
11/06/2003WO2003009804A3 Conformationally constrained parathyroid hormone (pth) analogs
1 ... 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 ... 243